The Peter Attia Drive, Episode #367

Title: Tylenol, pregnancy, and autism: What recent studies show and how to interpret the data
Release Date: October 6, 2025
Host: Dr. Peter Attia
Co-host: Nick Stenson

Brief Overview

This special episode addresses the recent controversy and media coverage surrounding the potential link between maternal use of acetaminophen (Tylenol) during pregnancy and increased autism risk in children. Dr. Peter Attia, joined by co-host Nick Stenson, scrutinizes the state of the scientific evidence, walks through the new studies prompting headlines, and provides a deep-dive lesson in careful, critical appraisal of observational research—especially in emotionally and politically charged contexts. The goal: to clarify the data, dispel misconceptions, and help listeners develop the tools to assess similar health claims in the future.

Key Discussion Points and Insights

1. Setting the Stage: Autism, Complexity, and Critical Thinking

• Autism rates have sharply risen: According to CDC data, from 6.7/1,000 children in 2000 to 32.2/1,000 recently—a five-fold increase ([15:17]).
• Complex conditions lack simple causes: "Complex conditions usually don't have simple explanations... Anytime we look at a possible contributing factor, we need to resist the temptation to assume it's the sole cause." — Peter Attia ([00:45]).
• Science is not apolitical: Both host and co-host stress their aim is to focus on evidence and avoid political debate ([02:00]).
• Humans aren't intuitively scientific: "We are not wired for critical and scientific thought...the scientific method is a human invention." — Peter Attia ([03:35]).

Frameworks for Analysis

• FDA risk categories for pregnancy: Overview of the "A/B/C/D/X" system for drug safety in pregnancy ([08:45]).
  • Tylenol (acetaminophen) is traditionally in Category B: generally considered safe, but new questions have arisen.
• The Bradford Hill Criteria: Nine principles for determining causality in epidemiology, including strength of association, consistency, plausibility, etc. ([05:38], [43:41], [46:41]).

2. The Current Controversy: Tylenol, Pregnancy & Autism

What Triggered the Headlines? ([13:52]–[23:11])

• Recent media concern was prompted by an August 2025 review in BMC Environmental Health.
  • The review was not a meta-analysis, but a summary of prior observational studies examining acetaminophen use during pregnancy and child neurodevelopmental disorders ([22:06]).
• Key Claim: Maternal acetaminophen use is associated with a higher risk of autism in offspring.

Dissecting the Data ([23:18]–[35:01])

• Six observational studies met criteria for the review; their findings varied.
  • Two found no significant association, three assessed dose-response (degree of exposure), but with substantial methodological weaknesses.
  • Example: The Xi 2020 study, which used a single cord blood measure at birth—a poor proxy for overall pregnancy exposure.
    • "Acetaminophen is eliminated from the body within 24 hours..." — Peter Attia ([23:18]).
    • Bias issue: The Xi study over-represented autism cases due to participant selection; 11% autism rate in the cohort vs. ~3% in population ([27:52]).
• Pooled relative risk: The association between acetaminophen and autism was only about 5% increased relative risk ([27:52]).
  • Main findings were dominated by the large Swedish cohort study.

Deep Dive: The Swedish and Japanese Cohort Studies ([35:01]–[43:27])

• Swedish Study:
  • Prospective study of 2.5 million children ([35:10]).
  • Found a small (5%) increased risk in the general cohort, but no risk when comparing siblings discordant for exposure (within the same family and genetics) ([38:04]).
  • Quote: "This suggests the apparent link observed in the full cohort was likely due to confounding factors" ([38:08]).
• Japanese Study:
  • ~220,000 children, 40% exposed to acetaminophen ([41:05]).
  • Similar results: A small, statistically insignificant association in the general analysis, abolished in sibling comparisons.
• Conclusion: "It's very difficult to make a strong case for causality." — Peter Attia ([41:05]).

3. Interpreting Observational Data: Why Causality is Hard ([43:27]–[46:29])

• Observational data is prone to confounding variables—hidden factors that explain associations (e.g., ice cream and drowning both correlated with heat, not each other).
• Randomized controlled trials (RCTs) would resolve causality, but are unethical or impractical in pregnancy contexts.

The Bradford Hill Criteria Examined for Acetaminophen and Autism ([46:41]–[56:32])

• Strength: Effect size is weak (1.05x); far below what is considered suggestive in pharmacology epidemiology ([49:17]).
• Consistency: Moderately consistent, but associations vanish with better controls ([49:26]).
• Specificity: Weak—many things correlate with autism ([50:09]).
• Temporality: Use does precede autism, but exposure window is unclear ([51:19]).
• Dose dependency: Mild and inconsistent ([52:29]).
• Biological plausibility: Mechanism for Tylenol causing autism is speculative at best ([52:59]).
• Analogy: Similar drugs (e.g., aspirin) appear protective, not harmful ([54:44]).
• Experimental evidence, coherence: Lacking, animal studies inconsistent or irrelevant ([54:49]).

Summing up the Science ([56:32]–[57:08])

• "Probability that if a woman takes Tylenol during pregnancy, it's going to increase the probability that her child has autism is very low." — Peter Attia ([57:08]).

4. Contextualizing the Autism Increase ([58:16]–[75:03])

• Genetics is the primary risk: 80–90% of autism variability is heritable ([59:25]).
• Most of the rise in diagnoses: Due to expanded criteria (DSM changes), increased awareness, and shifts in diagnostic practices ([65:11]).
  • Expanded criteria: 40–60% of the rise
  • Awareness: 20–30%
• Other contributors: Advancing paternal/maternal age, maternal obesity, preterm birth, air pollution ([69:24]).
• Acetaminophen as a risk? Possible, but contribution would be "very, very small" even in a worst-case scenario ([73:32]).

5. Practical Advice: Acetaminophen Use in Pregnancy ([75:03]–[82:22])

General Principle

• Avoid unnecessary medications in pregnancy.
  • "As a general rule, I would advise women to stop taking medications when they get pregnant. But medications aren't the only potential threat to the unborn child. The health of the mother is also important..." — Peter Attia ([75:19]).
• Risk-benefit must be assessed:
  • Some medications (e.g., thyroid hormone) are essential despite theoretical risk.
  • For mild pain, it may be wise to forego Tylenol; for fever or severe pain, careful use is justified, as fever itself poses a greater risk ([79:51]).

FDA Risk Category Recap ([77:21])

• Category A: Well-proven safe (thyroid hormone, prenatal vitamins).
• Category B: No proven risk (acetaminophen, metformin).
• Category C: Unclear risk/benefit (most drugs).
• Category D: Known risk but benefit sometimes outweighs (anticonvulsants, NSAIDs—third trimester).
• Category X: Definitive risk, avoid in pregnancy (statins, methotrexate).

Benefits of Tylenol in Pregnancy ([79:51])

• Fever control is critical: Untreated fever linked to birth defects and higher autism risk than acetaminophen itself.
• In severe or persistent pain, Tylenol is usually preferable to alternatives (NSAIDs, opioids) due to known risks with those classes.

6. Notable Quotes & Memorable Moments

• “Complex conditions require multiple things, typically… we need to resist the temptation to assume it's the sole cause.” — Peter Attia ([00:56])
• “We are not wired for critical and scientific thought… [the scientific method] doesn’t come naturally and it doesn't mean we're wired to do it.” — Peter Attia ([03:35])
• Memorable Critique of Media Hype: “It is literally impossible to disprove the link between any variable and autism... But we can't do that in epidemiology, and I think that's why these ideas persist.” — Peter Attia ([21:22])
• “A thousand sows' ears makes not a pearl necklace.” — Peter Attia, quoting James Yang on the pitfalls of meta-analyses with weak included data ([34:25])
• “For minor aches and pains, maybe it's best to just err on the side of caution and skip the acetaminophen. Whereas when the pain becomes really a nuisance… then judicious use of acetaminophen can help with the oversight of your physician.” — Peter Attia ([82:29])
• Challenge to Listeners: “If you just want sound bites, this isn’t the podcast for you. But if you want to be able to learn to think for yourself, then that's what we're here to do.” — Peter Attia ([82:29])

Important Segment Timestamps (HH:MM:SS)

• Intro & Frameworks: 00:11–13:52
• What are the claims linking acetaminophen & autism?: 13:52–23:18
• Reviewing the recent studies: 23:18–35:01
• The Swedish & Japanese cohort studies, sibling analyses: 35:01–43:41
• How to interpret observational research: 43:41–46:29
• Bradford Hill criteria applied: 46:29–56:32
• Bottom line on causality: 56:32–58:16
• What really explains autism’s increase?: 58:16–69:24
• Other environmental contributors: 69:24–75:03
• Practical advice for pregnant women: 75:03–82:22
• Closing thoughts and call for critical thinking: 82:22–end

Takeaways

• Link Between Tylenol and Autism: Existing observational studies show, at most, a very small association. When robust controls are implemented (e.g., sibling studies), this association disappears.
• Probability of a causal link is very low: Based on effect size, confounding factors, and Bradford Hill criteria, causality is unlikely.
• Genetics and environment are the main risk contributors for autism: Medication use is dwarfed by factors like heritability, diagnostic practices, parental age, maternal health, and air pollution.
• Medication in pregnancy should be carefully weighed: Unnecessary drugs should be avoided, but not at the expense of maternal or fetal health. Tylenol remains the safest fever/pain reducer available when needed in pregnancy.
• Critical thinking is essential: Assess claims using rigorous logic and evidence, not headlines or anecdotes.

Final Message

“Any one potential risk can’t be considered in isolation. You have to look at the full picture. The risk of a given intervention like Tylenol, as well as the potential risks of not taking Tylenol. As well as the nature and magnitude of those risks.” — Peter Attia ([82:29])

For further resources and a deeper dive, refer to the show notes at peterattiamd.com/shownotes.

(Advertisements, intros, outros, and non-content segments have been omitted from this summary.)